Cases of less‐than‐expected FVIII activity in previously treated patients during post‐marketing surveillance of N8‐GP

Abstract Introduction Turoctocog alfa pegol (N8‐GP) is a glycoPEGylated, extended half‐life (EHL), human recombinant factor VIII (FVIII) approved for the treatment and prevention of bleeding episodes in patients with haemophilia A. Since its launch in August 2019, > 800 patients have been treated worldwide. Aim To present data from identified post‐marketing cases of less‐than‐expected FVIII activity in previously treated patients (PTPs) without inhibitors after switching to N8‐GP. Methods The post‐marketing safety database was searched using keywords such as ‘coagulation FVIII level decreased’. Identified cases reported prior to 13 October 2021 were included in this report. Cases in which patients had FVIII inhibitors were excluded. Results Here we report 14 cases of less‐than‐expected FVIII activity. Details varied greatly amongst the cases. At presentation, FVIII activity ranged from 1% (15 min post‐dose) to 51% (2 days post‐dose). Seven patients experienced bleeding episodes after switching to N8‐GP with heterogeneity in bleeding presentations. Six out of seven patients who were tested for anti‐PEG IgG and/or IgM antibodies were positive. In all known cases, FVIII activity returned to the expected range when switched to an alternative FVIII replacement product. Conclusion In conclusion, the 14 reported cases of less‐than‐expected FVIII activity, without presence of detectable FVIII inhibitors, presented with heterogenous characteristics, and wide variations in FVIII activity and anti‐PEG antibody titre. FVIII activity returned to the expected range after switching to alternative FVIII products. In line with WFH guidelines, monitoring of FVIII activity can ensure FVIII activity in the expected range. The safety surveillance of N8‐GP continues.